• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Parkinsons drug

Anonymous

Guest
With you guys bringing the Cephalon CNS sales reps over, how much more voice and messaging do you need with Azilect since it's a 2nd position drug for you? Is there still a big need for more people detailing that product?